Related Experiment Video
Updated: Dec 22, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Bifidobacterium longum BL300 alleviates DSS-induced Colitis by promoting IgA-mediated Gut Microbiota homeostasis
Haowen Jin1, Hui Wang2, Xin Feng2
1Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, China Agricultural University, Beijing 100193, China. zhaizy@cau.edu.cn.
Abstract:
Inflammatory bowel disease (IBD) is a chronic disease that is related to excessive inflammation and an imbalance in the gut microbiota. In this study, the effect of five Bifidobacterium longum subsp. longum strains on alleviating the colitis induced by dextran sulfate sodium (DSS) was investigated. Disease activity index (DAI) scores combined with hematoxylin and eosin (H&E) analysis showed that only B. longum BL300 could significantly alleviate DSS-induced colitis. Furthermore, immunofluorescence analysis confirmed that the expression of the intestinal barrier-related protein ZO-1, occludin, claudin-1 and MUC2 was significantly up-regulated. Moreover, transcriptome analysis of the colon tissue combined with RT-qPCR analysis revealed that levels of pro-inflammatory cytokines IL-2, IL-6, IL-17, TNF-α and IL-1β were decreased and anti-inflammatory cytokine IL-10 level was increased after B. longum BL300 intervention. Notably, the IgA production immune network was activated by B. longum BL300, which eliminated pathogenic bacteria, such as Escherichia, Shigella, Enterobacter and Prosthecobacter, by forming complexes. Meanwhile, the relative abundance of SCFA-producing bacteria was significantly increased. These results highlight the anti-inflammatory effect of B. longum BL300 on DSS-induced colitis, indicating its use as a probiotic candidate to support recovery from ongoing colitis.
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...

